

Dr. Yibin Wang is currently a full Professor and Director of Signature Research Program in Cardiovascular and Metabolic Diseases at DukeNUS Medical School, Singapore, Senior PI at National Heart Center of Singapore, and Professor of Medicine at Duke University School of Medicine, Durham USA.

Dr. Wang received his Ph.D. in molecular genetics and cell biology from Baylor College of Medicine, Houston, Texas, and post-doctoral training in neurobiology and molecular cardiology at The Scripps Research Institute and University of California at San Diego. Dr. Wang's research mainly focuses on genetic basis and molecular mechanisms of heart failure and metabolic disorders, with more than 280 peer-reviewed publications in many leading journals in the field with an H-index of 93 (Google Scholar). His main research accomplishments include dissection of stress-signaling in heart diseases, discovery of novel regulators of cardiometabolic regulation through systems genetic approaches, and more recently on amino acid signaling and regulation, and nutrient signaling in cardiometabolic diseases. He currently serves as an Associate Editor for *Journal of Molecular and Cellular Cardiology*, *JACC, Asia* and *Journal of Cardiovascular Aging*, a guest Associate Editor for *Circulation* and a member of the editorial board for *Circulation Research* and *Journal of Biological Chemistry*. Dr. Wang has supervised more than 30 Ph.D. students and served as the course director and Vice Chair of the Molecular, Cellular and Integrated Physiology Ph.D. program at UCLA. Dr. Wang received an Established Investigator Award from American Heart Association and was the Thomas Smith Memorial Lecturer at 2016 American Heart Association Scientific Session. Dr. Wang was the recipient of 2021 Excellence in Educational Innovation Award from UCLA College of Life Science, as well as the 2023 Basic Research Prize from American Heart Association. Dr. Wang holds 4 patents including three licensed, and he is the scientific founder and member of the scientific advisory board of a start-up biotech company.